Skip to main content
. Author manuscript; available in PMC: 2018 Oct 31.
Published in final edited form as: Adv Exp Med Biol. 2017;994:275–284. doi: 10.1007/978-3-319-55947-6_15

Fig. 15.4.

Fig. 15.4

Glycan marker gpC1 is expressed in significant numbers of CTCs in Stage IV breast cancer patients. (a) FAST-scan images of bCTCs. Upper panels: Co-staining of C1 (green) and DAPI (blue); Bottom panels: co-staining of anti-CK (red) and DAPI (blue). (b) Distribution of gpC1–positive and -negative bCTCs in five subjects. C1-staining of bCTCs was semi-quantitatively measured by the FAST scan as antibody negative (blue), 1+ (purple), 2+ (green), and 3+ (red) as described. A patient with triple-negative BCa (ID# 189370) was measured gpC1–positive in 37 of 40 CTCs with 50% scored as strong positive (2+ and 3+). (ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2). (c) A summary of patients’ demographics and clinical characteristics (Adapted from Wang et al. 2015a)